Humira Biosimilars – Summer of Blockbuster Releases for Navitus to Review

This summer has seen a continuation of the long-awaited market entry of Humira® (adalimumab) biosimilars. As of July 1, nine additional biosimilars have been released.

What is a biosimilar?

The FDA defines a biosimilar as a biological product that is highly similar to an FDA-approved biologic (known as the reference product) and used in the prevention or treatment of disease. While not chemically identical, a biosimilar has no clinically meaningful difference from a reference product. It is FDA-approved for use after rigorous evaluation and testing is demonstrated by the manufacturer applicant. While not a traditional generic medication, biosimilars have the potential to introduce greater competition into the marketplace and drive down associated cost.

what action is navitus taking?

Several factors are present with these new biosimilars that require diligence and review. Each can differ not only in launch price and rebate opportunities, but also dosing concentrations, citrate-free formula options, and interchangeability with the reference product. Navitus recommends that all factors require consideration when selecting preferred formulary options.

In the past, many plan sponsors and PBMs have preferred high-list price/high-rebate products over low-cost options. The market saw both options offered with the release of the first Humira biosimilar in February and the mid-year entrants also have multiple list price options with varying rebating opportunities. This requires a multifaceted review framework that considers the potential for future adjustments to discounts and rebates and various incentive preferences. The decision of which to include in formularies cannot, and should not, be hasty.

At this time Navitus is reviewing each launched biosimilar product through our standard formulary evaluation process. We are committed to making medications more affordable for the people who need them and are deploying established clinical and financial review processes to assess and determine inclusion on standard formularies.

While these evaluations take time, our focus remains to determine what best achieves clinical appropriateness and cost savings for clients and members. We anticipate making a decision in our August Pharmacy and Therapeutics (P&T) Committee meeting.

WRITTEN BY BRENT EBERLE

As Senior Vice President, Chief Pharmacy Officer, Brent oversees Navitus’ health strategies division, which is responsible for clinical and population health initiatives, drug utilization review programs, formulary and rebate management, and specialty pharmacy operations.

Stay Informed and Connected

Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.

Examining Trends that Drive Informed Decisions

Now Available: 8th Annual Drug Trend Report

See the latest results and access industry insights you need to navigate current trend drivers.

Related blogs

Navigating Healthcare and Improving Outcomes

Achieving Outstanding Results with Tailored Network Strategies

Achieving Outstanding Results with Tailored Network Strategies

A medium-sized city in Michigan with 1,350 members was seeking ways to lower its pharmacy benefit costs, which were growing under its existing traditional pharmacy benefit manager (PBM). With its member covered by a two-tier, open formulary including…

Breaking Through Barriers with Value-Based Plan Design

Breaking Through Barriers with Value-Based Plan Design

Facing increased pharmacy benefit expenses, Blain’s Farm and Fleet, a Midwestern employer group, desired to improve plan performance. Specifically it was interested in educating eligible members about the benefits available to them, promoting cost-effective…

Finding a Solution to Lower Prescription Drug Costs

Finding a Solution to Lower Prescription Drug Costs

The Rural Arizona Group Health Trust (RAGHT) wanted to gain better control of its escalating drug trend with its large, traditional pharmacy benefit manager (PBM). Having only worked with traditional PBMs in the past, RAGHT was interested in exploring…

Empowered by Strategic Opportunities and Service Excellence

Empowered by Strategic Opportunities and Service Excellence

Putnam | Northern Westchester Health Benefits Consortium (PNW HBC) was the first municipal cooperative health plan in the state of New York to become certified by the Department of Insurance. They are dedicated to meeting — and exceeding — the standards…

QUALYiQ Program Delivers Significant Savings for Both Members and Health Plans

QUALYiQ Program Delivers Significant Savings for Both Members and Health Plans

As part of their treatment plan for hypophosphatasia (HPP), a rare genetic disorder affecting bone and teeth development, one of our members required Strensiq, a medication designed to manage HPP. However, Strensiq’s annual treatment costs ranged from…

RISE: Reporting and Intervention for Stars Excellence

RISE: Reporting and Intervention for Stars Excellence

RISE is a comprehensive Star Ratings Improvement program that focuses on positive outcomes for Medicare Part D (Part D) clinical measures, including: medication adherence for diabetes medications, medication adherence for hypertension, medication adherence…

Medication Therapy Management: Improving Health Outcomes and Reducing Cost

Medication Therapy Management: Improving Health Outcomes and Reducing Cost

Patients with chronic diseases can face greater risks for medication-related challenges such as non-adherence. This can lead to poor health outcomes and higher plan costs. That’s why we developed an MTM program, offered through our Clinical Engagement…

Personalized Member Transitions: Creating a Smoother Benefit Transition

Personalized Member Transitions: Creating a Smoother Benefit Transition

Navigating benefit transitions is no easy task. Our personalized member transition (PMT) program makes it smoother for both plan sponsors and members. Through our high-touch outreach to members, we eliminate gaps in care, minimize member disruption, improve…

Pharmacy and Practitioner Exclusions and How to Resolve Them

Pharmacy and Practitioner Exclusions and How to Resolve Them

Prescribers and Pharmacies can be deemed ineligible for providing services to government programs like Medicare, Medicaid or even to payers who are participating in government programs. Being ineligible to provide those services is commonly referred to…

previous arrow
next arrow